Glucocorticoids as adjunctive therapy for severe myelosuppression induced by combined immune checkpoint inhibitor and chemotherapy: a case report and literature review - Takeaways - MDSpire

Glucocorticoids as adjunctive therapy for severe myelosuppression induced by combined immune checkpoint inhibitor and chemotherapy: a case report and literature review

  • By

  • Shimin Tang

  • Na Li

  • Ji Ma

  • May 1, 2026

  • 0 min

Share

  • 1

    This study presents a retrospective case series of two lung cancer patients with severe myelosuppression after ICI and chemotherapy.

  • 2

    Both patients achieved full hematologic recovery with high-dose glucocorticoids and standard supportive care.

  • 3

    Significant myelosuppression post-ICI-chemotherapy is attributed to multiple factors, necessitating timely differential diagnosis.

  • 4

    Immediate glucocorticoid administration is essential if ICI-associated toxicity is suspected in patients.

  • 5

    Further large-scale studies are needed to establish optimal glucocorticoid dosing and treatment duration for myelosuppression.

Original Source(s)

Glucocorticoids as adjunctive therapy for severe myelosuppression induced by combined immune checkpoint inhibitor and chemotherapy: a case report and literature review

  • by Shimin Tang, Na Li, Ji Ma

  • May 1, 2026

Related Content

Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry